Tailoring access to high cost, genetically targeted drugs
| Data(s) |
20/06/2005
|
|---|---|
| Resumo |
Assessment of real cost effectiveness, with data linked to individual health outcomes while protecting patient privacy, is an essential challenge we need to meet |
| Identificador | |
| Idioma(s) |
eng |
| Publicador |
Australasian Medical Publishing Co. |
| Palavras-Chave | #Medicine, General & Internal #C1 #329902 Medical Biotechnology #730108 Cancer and related disorders |
| Tipo |
Journal Article |
